Art. -Nr.: HY-124447

BTYNB

Kundenbewertung

Based on 1 Customer Validation

BTYNB is a structure-specific nucleic acid binder and IGF2BP1 inhibitor (with an IC₅₀ of 5 μM against hBTYNB). BTYNB disrupts the IGF2BP1-RNA interaction and blocks its binding to oncogenic mRNAs such as c-Myc, MDM2, PD-L1. BTYNB completely blocks the INHBA-Smad2/3 pathway, disrupts the MYCN/IGF2BP1 loop, and thereby induces apoptosis and cell cycle arrest, effectively inhibiting the proliferation and survival of cancer cells. In addition, BTYNB acts as an immune activator and tumor microenvironment modulator, enhances T cell-mediated tumor killing, and produces significant synergistic effects with inhibitors of PD-1, BRD and BIRC5. BTYNB can be used in relevant research on various malignant tumors including ovarian cancer, neuroblastoma, leukemia and melanoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.0%
CAS. Nr.: 304456-62-0
Formel: C₁₂H₉BrN₂OS
Molecular Weight:309.18

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

BTYNB Chemical Structure

CAS. Nr.: 304456-62-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 5 μM (IMP1 c-Myc mRNA internation)^[1]

Alle TGF-beta/Smad Isoform-spezifische Produkte anzeigen :

Smad1
Smad3

Cellular Effect

Cell Line	Type	Value	Description	References
HL-60	IC₅₀	21.56 μM Compound: 2; BTYNB	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38382391]
K562	IC₅₀	6.76 μM Compound: 2; BTYNB	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38382391]

In Vitro

BTYNB (20 μM; 24-36 h) significantly inhibits the migration and invasion of KYSE30 and TE1 ESCC cells in vitro^[2].
BTYNB (10 μM; 48 h) significantly increases apoptosis in KYSE30 and TE1 ESCC cells^[2].
BTYNB (0.38-24 µM; 72 h) combined with Mivebresib exhibits strong synergy in reducing BE(2)-C human neuroblastoma cell viability after 72 hours of treatment^[3].
BTYNB (7-21 μM; 24 h) induces mild apoptosis in human HL60 and K562 leukemic cells after 24 h of treatment, accompanied by significant upregulation of the pro-apoptotic gene BAK^[4].
BTYNB (7-21 μM; 24 h) induces S-phase cell cycle arrest in human K562 leukemic cells (with no effect on HL60 cells) after 24 h of treatment, accompanied by significant upregulation of the cell cycle arrest gene p21 in both cell lines^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay ^[2]

Cell Line:

KYSE30, TE1 esophageal squamous cell carcinoma (ESCC) cells
Concentration:

20 μM
Incubation Time:

36 h (KYSE30 cells); 24 h (TE1 cells)
Result:

Reduced the relative cell area covered by invading KYSE30 cells to approximately 30% of control levels.
Reduced the relative cell area covered by migrating KYSE30 cells to approximately 40% of control levels.
Reduced the relative cell area covered by invading TE1 cells to approximately 20% of control levels.
Reduced the relative cell area covered by migrating TE1 cells to approximately 10% of control levels.

In Vivo

Combination of BTYNB (40 mg/kg; i.p.; twice weekly) with anti-PD-1 blockade therapy significantly improves the median survival of mice, reduces tumor cell burden, and converts the tumor microenvironment to a more immunoresponsive state^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6NCrl mice (female, 6 weeks old, intraperitoneal injection of 5 × 10⁶ ID8/Trp53^-/- cells)^[1]
Dosage:

40 mg/kg (monotherapy); 40 mg/kg (combination with anti-PD-1 antibody 8 mg/kg)
Administration:

i.p.; twice weekly
Result:

Improved median survival by ~30% compared to the control group and by 15% compared to anti-PD-1 monotherapy when combined with anti-PD-1 antibody.
Reduced tumor cell dominance in ascitic fluid to 67% when combined with anti-PD-1 antibody.
Shifted tumor cells to an immune-responsive phenotype when combined with anti-PD-1 antibody.
Increased immune cell accumulation in ascites (with a higher proportion of cytotoxic T cells than BTYNB monotherapy) when combined with anti-PD-1 antibody.

Chemical Information

CAS. Nr. 304456-62-0
Appearance Solid
Molecular Weight 309.18
Formel C₁₂H₉BrN₂OS
Color White to light yellow
SMILES

O=C(C1=CC=CC=C1/N=C/C2=CC=C(S2)Br)N
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 62.5 mg/mL (202.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2344 mL

16.1718 mL

32.3436 mL

5 mM

0.6469 mL

3.2344 mL

6.4687 mL

10 mM

0.3234 mL

1.6172 mL

3.2344 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Bley N, et al. Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancer. Signal Transduct Target Ther. 2025;10(1):419. Published 2025 Dec 25. [Content Brief]

[2]. Wang J J, et al. Elevated Expression of The RNA-Binding Protein IGF2BP1 Enhances The Mrna Stability and Translation E ciency of INHBA to Promote The Invasion and Migration of Esophageal Squamous Cancer Cells[J]. 2022.

[3]. Hagemann S, et al. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression[J]. Molecular cancer, 2023, 22(1): 88.

[4]. Jamal A, et al. BTYNB, an inhibitor of RNA binding protein IGF2BP1 reduces proliferation and induces differentiation of leukemic cancer cells. Saudi J Biol Sci. 2023;30(3):103569. [Content Brief]

[5]. Mahapatra L, et al. A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation. Transl Oncol. 2017;10(5):818-827. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2344 mL	16.1718 mL	32.3436 mL	80.8590 mL
	5 mM	0.6469 mL	3.2344 mL	6.4687 mL	16.1718 mL
	10 mM	0.3234 mL	1.6172 mL	3.2344 mL	8.0859 mL
	15 mM	0.2156 mL	1.0781 mL	2.1562 mL	5.3906 mL
	20 mM	0.1617 mL	0.8086 mL	1.6172 mL	4.0430 mL
	25 mM	0.1294 mL	0.6469 mL	1.2937 mL	3.2344 mL
	30 mM	0.1078 mL	0.5391 mL	1.0781 mL	2.6953 mL
	40 mM	0.0809 mL	0.4043 mL	0.8086 mL	2.0215 mL
	50 mM	0.0647 mL	0.3234 mL	0.6469 mL	1.6172 mL
	60 mM	0.0539 mL	0.2695 mL	0.5391 mL	1.3477 mL
	80 mM	0.0404 mL	0.2021 mL	0.4043 mL	1.0107 mL
	100 mM	0.0323 mL	0.1617 mL	0.3234 mL	0.8086 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

BTYNB

Apoptosis Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Glutamine Metabolism Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Alle TGF-beta/Smad Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BTYNB Related Classifications

HY-124447 Related Classifications